By the end of the month, the biopharmaceutical industry will have produced 9.3 billion doses of COVID-19 vaccines, says the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), as vaccine manufacturers renew their commitment to global vaccine equity.
Already, 3.3 billion of the world’s 5.8 billion adults have been vaccinated—but urgent steps are needed to reach the remaining 2.5 billion, says IFPMA (which includes BIO).
By the middle of next year, vaccine production should reach 24 billion—enough to give three shots to the entire world population of 7.9 billion.
The challenge now: how to distribute them. Members of the IFPMA have been cooperating through the WHO’s COVAX initiative, but as we’ve explained, we need to address trade restrictions, supply chain bottlenecks, and funding to get vaccines to people who need them.
The proposed waiver of the WTO TRIPS agreement for vaccine technology “has been overtaken by the facts,” says IFPMA. Clearly, the WTO does not need to waive IP rights to allow for sufficient global vaccine production.
Read: Why the TRIPS waiver wouldn’t work
Meanwhile, biopharma companies have already made 300 voluntary collaborations to get vaccines to countries in need: “In particular in Africa, a number of important agreements and commitments have been made to share know-how of mRNA and adenoviral vector vaccine platforms,” continues IFPMA.
The bottom line:IP protections are not the problem. Waiving IP protections and trying to replicate sophisticated production facilities would take much longer and cost a lot more money than sharing the vaccines we already have.
More Health Care News:
The New York Times: Why mix-and-match COVID boosters just might work
“The Food and Drug Administration seems likely to allow Americans to switch vaccines when choosing a COVID-19 booster shot. That authorization, which could come this week, is the latest development in a long-running debate over whether a mix-and-match strategy helps protect people from the coronavirus.”
BioNJ: Governor Phil Murphy celebrates groundbreaking of historic research, education and innovation hub in New Brunswick
The New Jersey Innovation and Technology Hub is “a 550,000 square foot development that will be a center of innovation, research and medical education in downtown New Brunswick.”